D L Carlson Investment Group Inc. Makes New $3.32 Million Investment in Zoetis Inc (NYSE:ZTS)

D L Carlson Investment Group Inc. bought a new position in Zoetis Inc (NYSE:ZTS) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 26,625 shares of the company’s stock, valued at approximately $3,317,000.

A number of other large investors have also recently made changes to their positions in ZTS. Tarbox Family Office Inc. lifted its position in shares of Zoetis by 74.4% during the 3rd quarter. Tarbox Family Office Inc. now owns 218 shares of the company’s stock valued at $27,000 after buying an additional 93 shares in the last quarter. JJJ Advisors Inc. purchased a new position in shares of Zoetis during the 2nd quarter valued at about $25,000. Prestige Wealth Management Group LLC purchased a new position in shares of Zoetis during the 2nd quarter valued at about $27,000. Tradewinds Capital Management LLC purchased a new position in shares of Zoetis during the 3rd quarter valued at about $31,000. Finally, Altshuler Shaham Ltd lifted its position in shares of Zoetis by 198.8% during the 2nd quarter. Altshuler Shaham Ltd now owns 254 shares of the company’s stock valued at $29,000 after buying an additional 169 shares in the last quarter. 89.95% of the stock is currently owned by institutional investors and hedge funds.

NYSE ZTS opened at $117.86 on Friday. The stock’s 50 day moving average is $125.46 and its 200 day moving average is $116.48. The company has a current ratio of 4.17, a quick ratio of 2.87 and a debt-to-equity ratio of 2.74. Zoetis Inc has a 12 month low of $78.90 and a 12 month high of $130.20. The stock has a market cap of $57.43 billion, a PE ratio of 37.65, a P/E/G ratio of 2.98 and a beta of 0.88.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.94 EPS for the quarter, topping the Zacks’ consensus estimate of $0.88 by $0.06. Zoetis had a return on equity of 72.86% and a net margin of 22.74%. The company had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.58 billion. During the same period in the previous year, the firm earned $0.83 EPS. The firm’s revenue was up 7.0% compared to the same quarter last year. On average, analysts forecast that Zoetis Inc will post 3.57 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Tuesday, October 22nd will be issued a $0.164 dividend. The ex-dividend date of this dividend is Monday, October 21st. This represents a $0.66 dividend on an annualized basis and a yield of 0.56%. Zoetis’s dividend payout ratio is presently 21.09%.

In related news, EVP Roxanne Lagano sold 4,463 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $125.99, for a total value of $562,293.37. Following the transaction, the executive vice president now directly owns 33,190 shares of the company’s stock, valued at approximately $4,181,608.10. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Clinton A. Jr. Lewis sold 6,123 shares of the business’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $128.62, for a total value of $787,540.26. Following the completion of the transaction, the executive vice president now directly owns 39,141 shares in the company, valued at $5,034,315.42. The disclosure for this sale can be found here. Over the last three months, insiders sold 34,332 shares of company stock worth $4,258,182. 0.29% of the stock is owned by insiders.

ZTS has been the topic of a number of analyst reports. JPMorgan Chase & Co. lifted their price objective on Zoetis from $145.00 to $150.00 and gave the company an “overweight” rating in a research report on Friday. Argus set a $140.00 price objective on Zoetis and gave the company a “buy” rating in a research report on Wednesday, September 4th. Morgan Stanley lifted their price objective on Zoetis from $100.00 to $136.00 and gave the company an “equal weight” rating in a research report on Monday, September 30th. Goldman Sachs Group initiated coverage on Zoetis in a research report on Monday, September 9th. They set a “conviction-buy” rating and a $145.00 price objective on the stock. Finally, Craig Hallum lifted their price objective on Zoetis from $132.00 to $138.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Eight equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $126.75.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

See Also: Which market index is the best?

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.